VT News
Chris Gratton

Chris Gratton

Ask VT AI
View News Summary
  • Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
  • Analysts warn investors to be cautious of multiple risky stocks facing headwinds, including MicroStrategy and GameStop for reliance on volatile assets.
  • Charity rowing team mistaken for 'illegal migrants' by MP, leading to multiple interventions, but crew uses attention to highlight fundraising for motor neurone disease research.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Latest News
Ask VT AI
View News Summary
  • Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
  • Analysts warn investors to be cautious of multiple risky stocks facing headwinds, including MicroStrategy and GameStop for reliance on volatile assets.
  • Charity rowing team mistaken for 'illegal migrants' by MP, leading to multiple interventions, but crew uses attention to highlight fundraising for motor neurone disease research.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Most Reported By
News from Chris Gratton

Top Topics

Trending in U.S.

World

Sport